Treatment of Substance Use Disorders

Introduction to Treatment

• Complete alcohol abstinence is the most important treatment goal, as recommended by the Clinical and Molecular Hepatology guidelines and the American Association for the Study of Liver Diseases 1
• The combination of pharmacotherapy and psychosocial interventions has been shown to be more effective than either approach alone, with abstinence being the most important treatment goal for reducing morbidity and mortality in alcohol dependence syndrome 1

Pharmacotherapy

• Acamprosate increases the probability of abstinence with moderate certainty evidence, resulting in a 38% success rate compared to 25% with placebo 2
• Acamprosate demonstrates reduced dropout rates, with 42% of patients remaining in treatment compared to 50% with placebo 2
• Acamprosate is effective for maintaining abstinence for up to 12 months after detoxification 2
• The following medications have varying efficacy and hepatotoxicity risks:

• Baclofen, Naltrexone, and Acamprosate are first-line options for patients with alcoholic cirrhosis, with moderate strength of evidence 3, 4, 5, 2
• Disulfiram is contraindicated due to high risk of hepatotoxicity, especially with severe alcohol consumption, with a high strength of evidence 3, 5, 4
• Benzodiazepines are recommended as first-line treatment for alcohol withdrawal syndrome, with long-acting benzodiazepines (chlordiazepoxide, diazepam) for prevention of seizures and lorazepam for patients with severe AWS, advanced age, liver failure, or other serious conditions, as recommended by the American Association for the Study of Liver Diseases 1

Psychosocial Interventions

• Brief interventions using the FRAMES model (Feedback, Responsibility, Advice, Menu, Empathy, Self-efficacy) are recommended for patients with ALD, as suggested by the American Association for the Study of Liver Diseases 1
• Support groups such as Alcoholics Anonymous, family therapy, and motivational enhancement therapy can help create a supportive environment for patients with ALD, as recommended by the American Association for the Study of Liver Diseases and the European Association for the Study of the Liver 1, 5
• Cognitive Behavioral Therapy (CBT) is an evidence-based approach to identify triggers for drinking, develop coping strategies, and prevent relapse, with a moderate strength of evidence, as recommended by the American College of Physicians, American family physician, and PLoS Medicine journals 3, 5, 6, 1, 7, 8
• Contingency Management provides tangible rewards for abstinence and is an effective approach when combined with pharmacotherapy and CBT, with a moderate strength of evidence 2, 9

Lifestyle Modifications

• Thiamine supplementation of 100-300 mg/day is recommended to prevent Wernicke encephalopathy 1
• Coffee consumption of ≥3 cups/day may have protective effects for patients with ALD, as suggested by the American Association for the Study of Liver Diseases 1
• Weight control is recommended for obese patients with ALD, as stated by the American Association for the Study of Liver Diseases 1
• Smoking cessation is necessary for patients with ALD, as smoking accelerates fibrosis, according to the American Association for the Study of Liver Diseases 1
• Abstinence from alcohol is necessary for patients with viral hepatitis (HBV, HCV), as recommended by the American Association for the Study of Liver Diseases 1
• Protein intake should be 1.2-1.5 g/kg/day, with caloric intake of 35-40 kcal/kg/day, and consideration of more frequent, smaller meals if needed, as recommended by the American Association for the Study of Liver Diseases, with a moderate strength of evidence 3, 1

Management of Complications

• Hepatic encephalopathy presents with confusion, disorientation, and asterixis, and can be managed with lactulose, rifaximin, and protein restriction as needed, according to the Journal of Hepatology guidelines, with a high strength of evidence 10
• Variceal bleeding requires immediate medical attention and should be treated as a medical emergency due to the high risk of mortality, with a high strength of evidence, as recommended by the American Association for the Study of Liver Diseases 11
• Benzodiazepines are the treatment of choice for acute withdrawal, and thiamine supplementation (100-300mg/day) should always be provided, with a high strength of evidence, as recommended by the American Society of Addiction Medicine 5, 6, 1, 12
• A symptom-triggered regimen rather than a fixed-dose schedule should be used for withdrawal management, with a high strength of evidence, as suggested by the American Society of Addiction Medicine 6
• Regular liver function tests are essential, especially with naltrexone therapy, to monitor for medication side effects and assess compliance with abstinence, with a high strength of evidence, as recommended by the American Association for the Study of Liver Diseases 3, 4, 13
• Screening for complications, such as hepatic encephalopathy, varices, ascites, and nutritional deficiencies, is crucial, with a high strength of evidence, as recommended by the Journal of Hepatology guidelines 3, 10

Relapse Prevention

• Continued pharmacotherapy for at least 6-12 months, ongoing participation in psychosocial interventions, and regular monitoring of liver function and overall health are essential for relapse prevention, with a moderate strength of evidence 3, 1, 5
• Addressing comorbid psychiatric conditions and developing strategies for relapse prevention are also crucial, with a moderate strength of evidence 3, 1, 5
• Patients with severe alcohol use disorder require immediate medically supervised detoxification followed by comprehensive treatment including pharmacotherapy and psychosocial interventions to achieve complete abstinence, as recommended by the National Institute on Alcohol Abuse and Alcoholism (NIAAA) 3
• A combined approach with pharmacotherapy and psychosocial interventions is essential, with a moderate strength of evidence 13, 1, 5